Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Joshua Lin and Team: New Evidence on Long-Term Anticoagulation for Unprovoked VTE 
Joshua Lin/LinkedIn
Dec 19, 2025, 11:45

Joshua Lin and Team: New Evidence on Long-Term Anticoagulation for Unprovoked VTE 

Joshua Lin, Executive Director of Mass General Brigham Center for Integrated Healthcare Data Research, posted on LinkedIn:

”New Evidence on Long-Term Anticoagulation for Unprovoked VTE

We are pleased to share our recent BMJ publication demonstrating that continuation of oral anticoagulant therapy beyond the initial 90-day treatment period after a first unprovoked venous thromboembolism (VTE) is associated with a significantly lower risk of recurrent thrombosis and all-cause mortality, compared with early discontinuation. Extended therapy, however, is also associated with a higher risk of major bleeding – underscoring the importance of individualized clinical decision-making.

Full study here.
Press Release here.”

Title: Continued versus discontinued oral anticoagulant treatment for unprovoked venous thromboembolism: target trial emulation

Authors: Kueiyu Joshua Lin, Dae Hyun Kim, Daniel E Singer, Yichi Zhang, Alexander Cervone, Anna R Kehoe, Katsiaryna Bykov

VTE

Stay updated with Hemostasis Today.

Alexander Cervone Anna R Kehoe Anticoagulation BMJ British Medical Journal Dae Hyun Kim Daniel E Singer Health Hematology Hemostasis Hemostasis Today Joshua Lin Katsiaryna Bykov Long-term Anticoagulation Mass General Brigham Center for Integrated Healthcare Data Research Medicine Oral Anticoagulant Treatment thrombosis Unprovoked VTE venous thromboembolism VTE Yichi Zhang
NewsFeed